Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Two initial aflibercept 8 mg loading doses in treatment-naive neovascular AMD
2025-523478-17-00Phase 4Authorised
- Sponsor
- Medical University of Graz
- Start
- Feb 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aflibercept in exudative macular degeneration, sponsored by Medical University of Graz. Primary endpoint: Proportion of patients without disease activity at week 8. Planned start Feb 2026; status: authorised.
02
Drugs
aflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2025-523478-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523478-17-00.